Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response
Background: It remains unclear how we can shorten the treatment duration of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C virus (HCV) genotype 2 infection who achieved a rapid virological response (RVR). Aim: We compared the efficacy of antivira...
Gespeichert in:
| Veröffentlicht in: | Liver international 2009-01, Vol.29 (1), p.120-125 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 125 |
|---|---|
| container_issue | 1 |
| container_start_page | 120 |
| container_title | Liver international |
| container_volume | 29 |
| creator | Toyoda, Hidenori Kumada, Takashi Kiriyama, Seiki Sone, Yasuhiro Tanikawa, Makoto Hisanaga, Yasuhiro Kanamori, Akira Atsumi, Hiroyuki Nakano, Satoshi Arakawa, Takahiro |
| description | Background: It remains unclear how we can shorten the treatment duration of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C virus (HCV) genotype 2 infection who achieved a rapid virological response (RVR).
Aim: We compared the efficacy of antiviral combination therapy with peginterferon and ribavirin for 8 vs. 24 weeks for the treatment of patients with HCV genotype 2 infection and with RVR.
Methods: Sixty‐one patients were enrolled. Serum HCV RNA was not detected at 4 weeks after the start of treatment in 32 patients with an RVR. These 32 patients were randomly assigned to 8‐week (n=15) or 24‐week (n=17) treatment regimens. Patients in the 8‐week group who relapsed underwent a 24‐week retreatment.
Results: No significant difference in patient characteristics was observed between the 8‐ and the 24‐week treatment groups. A sustained virological response (SVR) was seen in five of 15 patients (33.3%) in the 8‐week treatment group and 14 of 17 (82.4%) in the 24‐week treatment group; the rate was significantly higher in the 24‐week treatment group (P=0.0140). Nine of 10 relapsed patients in the 8‐week treatment group underwent a 24‐week retreatment, and seven achieved an SVR.
Conclusion: An 8‐week regimen of combination antiviral therapy with peginterferon and ribavirin yielded an increase in the relapse rate, indicating the limitation of a reduction of treatment below 12 weeks in patients with genotype 2, after RVR. |
| doi_str_mv | 10.1111/j.1478-3231.2008.01736.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_746227647</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66807076</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4686-f54537ffdbe8f2a2b3919e19794de7654fe9968df62a8aac10f572511620da0b3</originalsourceid><addsrcrecordid>eNqNksGO0zAQQCMEYpeFX0A-wSnFdhI7PnBA1bKsqOAA7B4tJxm37qZ2sF3aftz-2zqbqnACfLE1896MpZksQwTPSDrv1jNS8jovaEFmFON6hgkv2Gz_JDs_JZ6e3rQ4y16EsMaYCFGR59kZqYu6rIg4z-4vzXIV8x3AHfKwNBuwyGmkbDS_jFc9at2mMVZF4yyKK_BqOKCdiSs0JNpG8Bp8SinbIW8alSRjkXYeDckBG8NEt6tEmRatYIxHE9B8SvwZSPI2oCVYFw8DIPpYVaHU03Rj0vVuadr0KQ9hcDbAy-yZVn2AV8f7Ivvx8fL7_FO--Hp1Pf-wyNuS1SzXVVkVXOuugVpTRZtCEAFEcFF2wFlVahCC1Z1mVNVKtQTritOKEEZxp3BTXGRvp7qDdz-3EKLcmNBC3ysLbhskLxmlnJU8kW_-SjJWY445-ydIMeUlZyNYT2DrXQgetBy82Sh_kATLcRvkWo6DluPQ5bgN8nEb5D6pr489ts0Gut_icfwJeD8BO9PD4b8Ly8X1zfhKfj75JkTYn3zl7yTjBa_k7ZcrKfi36uZ28VmK4gHzW9bT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20274766</pqid></control><display><type>article</type><title>Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Toyoda, Hidenori ; Kumada, Takashi ; Kiriyama, Seiki ; Sone, Yasuhiro ; Tanikawa, Makoto ; Hisanaga, Yasuhiro ; Kanamori, Akira ; Atsumi, Hiroyuki ; Nakano, Satoshi ; Arakawa, Takahiro</creator><creatorcontrib>Toyoda, Hidenori ; Kumada, Takashi ; Kiriyama, Seiki ; Sone, Yasuhiro ; Tanikawa, Makoto ; Hisanaga, Yasuhiro ; Kanamori, Akira ; Atsumi, Hiroyuki ; Nakano, Satoshi ; Arakawa, Takahiro</creatorcontrib><description>Background: It remains unclear how we can shorten the treatment duration of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C virus (HCV) genotype 2 infection who achieved a rapid virological response (RVR).
Aim: We compared the efficacy of antiviral combination therapy with peginterferon and ribavirin for 8 vs. 24 weeks for the treatment of patients with HCV genotype 2 infection and with RVR.
Methods: Sixty‐one patients were enrolled. Serum HCV RNA was not detected at 4 weeks after the start of treatment in 32 patients with an RVR. These 32 patients were randomly assigned to 8‐week (n=15) or 24‐week (n=17) treatment regimens. Patients in the 8‐week group who relapsed underwent a 24‐week retreatment.
Results: No significant difference in patient characteristics was observed between the 8‐ and the 24‐week treatment groups. A sustained virological response (SVR) was seen in five of 15 patients (33.3%) in the 8‐week treatment group and 14 of 17 (82.4%) in the 24‐week treatment group; the rate was significantly higher in the 24‐week treatment group (P=0.0140). Nine of 10 relapsed patients in the 8‐week treatment group underwent a 24‐week retreatment, and seven achieved an SVR.
Conclusion: An 8‐week regimen of combination antiviral therapy with peginterferon and ribavirin yielded an increase in the relapse rate, indicating the limitation of a reduction of treatment below 12 weeks in patients with genotype 2, after RVR.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>EISSN: 1399-1698</identifier><identifier>DOI: 10.1111/j.1478-3231.2008.01736.x</identifier><identifier>PMID: 18384519</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Antiviral Agents - administration & dosage ; Antiviral Agents - pharmacology ; Antiviral Agents - therapeutic use ; chronic hepatitis C ; Chronic infection ; Drug Therapy, Combination ; Female ; genotype 2 ; Genotypes ; Hepacivirus - drug effects ; Hepacivirus - genetics ; Hepatitis C ; Hepatitis C virus ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - genetics ; Humans ; Interferon-alpha - administration & dosage ; Interferon-alpha - pharmacology ; Interferon-alpha - therapeutic use ; Liver ; Male ; Middle Aged ; peginterferon ; Polyethylene Glycols - administration & dosage ; Polyethylene Glycols - pharmacology ; Polyethylene Glycols - therapeutic use ; Recombinant Proteins ; Ribavirin ; Ribavirin - administration & dosage ; Ribavirin - pharmacology ; Ribavirin - therapeutic use ; RNA ; Statistics, Nonparametric ; sustained virological response ; Viremia</subject><ispartof>Liver international, 2009-01, Vol.29 (1), p.120-125</ispartof><rights>2009 The Authors. Journal compilation © 2009 Blackwell Publishing Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4686-f54537ffdbe8f2a2b3919e19794de7654fe9968df62a8aac10f572511620da0b3</citedby><cites>FETCH-LOGICAL-c4686-f54537ffdbe8f2a2b3919e19794de7654fe9968df62a8aac10f572511620da0b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1478-3231.2008.01736.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1478-3231.2008.01736.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27928,27929,45578,45579</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18384519$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Toyoda, Hidenori</creatorcontrib><creatorcontrib>Kumada, Takashi</creatorcontrib><creatorcontrib>Kiriyama, Seiki</creatorcontrib><creatorcontrib>Sone, Yasuhiro</creatorcontrib><creatorcontrib>Tanikawa, Makoto</creatorcontrib><creatorcontrib>Hisanaga, Yasuhiro</creatorcontrib><creatorcontrib>Kanamori, Akira</creatorcontrib><creatorcontrib>Atsumi, Hiroyuki</creatorcontrib><creatorcontrib>Nakano, Satoshi</creatorcontrib><creatorcontrib>Arakawa, Takahiro</creatorcontrib><title>Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>Background: It remains unclear how we can shorten the treatment duration of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C virus (HCV) genotype 2 infection who achieved a rapid virological response (RVR).
Aim: We compared the efficacy of antiviral combination therapy with peginterferon and ribavirin for 8 vs. 24 weeks for the treatment of patients with HCV genotype 2 infection and with RVR.
Methods: Sixty‐one patients were enrolled. Serum HCV RNA was not detected at 4 weeks after the start of treatment in 32 patients with an RVR. These 32 patients were randomly assigned to 8‐week (n=15) or 24‐week (n=17) treatment regimens. Patients in the 8‐week group who relapsed underwent a 24‐week retreatment.
Results: No significant difference in patient characteristics was observed between the 8‐ and the 24‐week treatment groups. A sustained virological response (SVR) was seen in five of 15 patients (33.3%) in the 8‐week treatment group and 14 of 17 (82.4%) in the 24‐week treatment group; the rate was significantly higher in the 24‐week treatment group (P=0.0140). Nine of 10 relapsed patients in the 8‐week treatment group underwent a 24‐week retreatment, and seven achieved an SVR.
Conclusion: An 8‐week regimen of combination antiviral therapy with peginterferon and ribavirin yielded an increase in the relapse rate, indicating the limitation of a reduction of treatment below 12 weeks in patients with genotype 2, after RVR.</description><subject>Adult</subject><subject>Aged</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - pharmacology</subject><subject>Antiviral Agents - therapeutic use</subject><subject>chronic hepatitis C</subject><subject>Chronic infection</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>genotype 2</subject><subject>Genotypes</subject><subject>Hepacivirus - drug effects</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis C</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - genetics</subject><subject>Humans</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Interferon-alpha - pharmacology</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Liver</subject><subject>Male</subject><subject>Middle Aged</subject><subject>peginterferon</subject><subject>Polyethylene Glycols - administration & dosage</subject><subject>Polyethylene Glycols - pharmacology</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Recombinant Proteins</subject><subject>Ribavirin</subject><subject>Ribavirin - administration & dosage</subject><subject>Ribavirin - pharmacology</subject><subject>Ribavirin - therapeutic use</subject><subject>RNA</subject><subject>Statistics, Nonparametric</subject><subject>sustained virological response</subject><subject>Viremia</subject><issn>1478-3223</issn><issn>1478-3231</issn><issn>1399-1698</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNksGO0zAQQCMEYpeFX0A-wSnFdhI7PnBA1bKsqOAA7B4tJxm37qZ2sF3aftz-2zqbqnACfLE1896MpZksQwTPSDrv1jNS8jovaEFmFON6hgkv2Gz_JDs_JZ6e3rQ4y16EsMaYCFGR59kZqYu6rIg4z-4vzXIV8x3AHfKwNBuwyGmkbDS_jFc9at2mMVZF4yyKK_BqOKCdiSs0JNpG8Bp8SinbIW8alSRjkXYeDckBG8NEt6tEmRatYIxHE9B8SvwZSPI2oCVYFw8DIPpYVaHU03Rj0vVuadr0KQ9hcDbAy-yZVn2AV8f7Ivvx8fL7_FO--Hp1Pf-wyNuS1SzXVVkVXOuugVpTRZtCEAFEcFF2wFlVahCC1Z1mVNVKtQTritOKEEZxp3BTXGRvp7qDdz-3EKLcmNBC3ysLbhskLxmlnJU8kW_-SjJWY445-ydIMeUlZyNYT2DrXQgetBy82Sh_kATLcRvkWo6DluPQ5bgN8nEb5D6pr489ts0Gut_icfwJeD8BO9PD4b8Ly8X1zfhKfj75JkTYn3zl7yTjBa_k7ZcrKfi36uZ28VmK4gHzW9bT</recordid><startdate>200901</startdate><enddate>200901</enddate><creator>Toyoda, Hidenori</creator><creator>Kumada, Takashi</creator><creator>Kiriyama, Seiki</creator><creator>Sone, Yasuhiro</creator><creator>Tanikawa, Makoto</creator><creator>Hisanaga, Yasuhiro</creator><creator>Kanamori, Akira</creator><creator>Atsumi, Hiroyuki</creator><creator>Nakano, Satoshi</creator><creator>Arakawa, Takahiro</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>200901</creationdate><title>Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response</title><author>Toyoda, Hidenori ; Kumada, Takashi ; Kiriyama, Seiki ; Sone, Yasuhiro ; Tanikawa, Makoto ; Hisanaga, Yasuhiro ; Kanamori, Akira ; Atsumi, Hiroyuki ; Nakano, Satoshi ; Arakawa, Takahiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4686-f54537ffdbe8f2a2b3919e19794de7654fe9968df62a8aac10f572511620da0b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - pharmacology</topic><topic>Antiviral Agents - therapeutic use</topic><topic>chronic hepatitis C</topic><topic>Chronic infection</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>genotype 2</topic><topic>Genotypes</topic><topic>Hepacivirus - drug effects</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis C</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - genetics</topic><topic>Humans</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Interferon-alpha - pharmacology</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Liver</topic><topic>Male</topic><topic>Middle Aged</topic><topic>peginterferon</topic><topic>Polyethylene Glycols - administration & dosage</topic><topic>Polyethylene Glycols - pharmacology</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Recombinant Proteins</topic><topic>Ribavirin</topic><topic>Ribavirin - administration & dosage</topic><topic>Ribavirin - pharmacology</topic><topic>Ribavirin - therapeutic use</topic><topic>RNA</topic><topic>Statistics, Nonparametric</topic><topic>sustained virological response</topic><topic>Viremia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Toyoda, Hidenori</creatorcontrib><creatorcontrib>Kumada, Takashi</creatorcontrib><creatorcontrib>Kiriyama, Seiki</creatorcontrib><creatorcontrib>Sone, Yasuhiro</creatorcontrib><creatorcontrib>Tanikawa, Makoto</creatorcontrib><creatorcontrib>Hisanaga, Yasuhiro</creatorcontrib><creatorcontrib>Kanamori, Akira</creatorcontrib><creatorcontrib>Atsumi, Hiroyuki</creatorcontrib><creatorcontrib>Nakano, Satoshi</creatorcontrib><creatorcontrib>Arakawa, Takahiro</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toyoda, Hidenori</au><au>Kumada, Takashi</au><au>Kiriyama, Seiki</au><au>Sone, Yasuhiro</au><au>Tanikawa, Makoto</au><au>Hisanaga, Yasuhiro</au><au>Kanamori, Akira</au><au>Atsumi, Hiroyuki</au><au>Nakano, Satoshi</au><au>Arakawa, Takahiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2009-01</date><risdate>2009</risdate><volume>29</volume><issue>1</issue><spage>120</spage><epage>125</epage><pages>120-125</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><eissn>1399-1698</eissn><abstract>Background: It remains unclear how we can shorten the treatment duration of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C virus (HCV) genotype 2 infection who achieved a rapid virological response (RVR).
Aim: We compared the efficacy of antiviral combination therapy with peginterferon and ribavirin for 8 vs. 24 weeks for the treatment of patients with HCV genotype 2 infection and with RVR.
Methods: Sixty‐one patients were enrolled. Serum HCV RNA was not detected at 4 weeks after the start of treatment in 32 patients with an RVR. These 32 patients were randomly assigned to 8‐week (n=15) or 24‐week (n=17) treatment regimens. Patients in the 8‐week group who relapsed underwent a 24‐week retreatment.
Results: No significant difference in patient characteristics was observed between the 8‐ and the 24‐week treatment groups. A sustained virological response (SVR) was seen in five of 15 patients (33.3%) in the 8‐week treatment group and 14 of 17 (82.4%) in the 24‐week treatment group; the rate was significantly higher in the 24‐week treatment group (P=0.0140). Nine of 10 relapsed patients in the 8‐week treatment group underwent a 24‐week retreatment, and seven achieved an SVR.
Conclusion: An 8‐week regimen of combination antiviral therapy with peginterferon and ribavirin yielded an increase in the relapse rate, indicating the limitation of a reduction of treatment below 12 weeks in patients with genotype 2, after RVR.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>18384519</pmid><doi>10.1111/j.1478-3231.2008.01736.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2009-01, Vol.29 (1), p.120-125 |
| issn | 1478-3223 1478-3231 1399-1698 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_746227647 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adult Aged Antiviral Agents - administration & dosage Antiviral Agents - pharmacology Antiviral Agents - therapeutic use chronic hepatitis C Chronic infection Drug Therapy, Combination Female genotype 2 Genotypes Hepacivirus - drug effects Hepacivirus - genetics Hepatitis C Hepatitis C virus Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - genetics Humans Interferon-alpha - administration & dosage Interferon-alpha - pharmacology Interferon-alpha - therapeutic use Liver Male Middle Aged peginterferon Polyethylene Glycols - administration & dosage Polyethylene Glycols - pharmacology Polyethylene Glycols - therapeutic use Recombinant Proteins Ribavirin Ribavirin - administration & dosage Ribavirin - pharmacology Ribavirin - therapeutic use RNA Statistics, Nonparametric sustained virological response Viremia |
| title | Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T08%3A40%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Eight-week%20regimen%20of%20antiviral%20combination%20therapy%20with%20peginterferon%20and%20ribavirin%20for%20patients%20with%20chronic%20hepatitis%20C%20with%20hepatitis%20C%20virus%20genotype%202%20and%20a%20rapid%20virological%20response&rft.jtitle=Liver%20international&rft.au=Toyoda,%20Hidenori&rft.date=2009-01&rft.volume=29&rft.issue=1&rft.spage=120&rft.epage=125&rft.pages=120-125&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/j.1478-3231.2008.01736.x&rft_dat=%3Cproquest_cross%3E66807076%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20274766&rft_id=info:pmid/18384519&rfr_iscdi=true |